TD Cowen initiated coverage on Verona Pharma with a new price target
$VRNA
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2025 | $100.00 | Buy | TD Cowen |
| 4/21/2025 | $80.00 | Overweight | Cantor Fitzgerald |
| 1/10/2025 | $68.00 | Buy | ROTH MKM |
| 10/3/2024 | $50.00 | Overweight | Wells Fargo |
| 5/22/2023 | $35.00 → $38.00 | Buy | Jefferies |
| 9/19/2022 | $27.00 | Outperform | Wedbush |
| 8/26/2022 | $31.00 | Overweight | Piper Sandler |
| 11/12/2021 | $18.00 → $23.00 | Buy | Canaccord Genuity |
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition, John Schmid has decided not to stand for re-election at the Company's 2025 Annual Stockholders Meeting, at which time the size of the Board will be reduced to eight members. "I am honored to welcome Jim to our Board of Direc
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E
144 - Verona Pharma plc (0001657312) (Subject)
10-Q - Verona Pharma plc (0001657312) (Filer)
8-K - Verona Pharma plc (0001657312) (Filer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide
SC 13G/A - Verona Pharma plc (0001657312) (Subject)
SC 13G/A - Verona Pharma plc (0001657312) (Subject)
SC 13G - Verona Pharma plc (0001657312) (Subject)
TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00
Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00
ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)